[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spastic-paraplegia-4\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spastic-paraplegia-4":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100558657","spastic-paraplegia---centers-of-excellence-research-network-100558657",false,"NCT06553976","Spastic Paraplegia - Centers of Excellence Research Network","Spastic Paraplegia - Centers of Excellence Research Network (SP-CERN) - Natural History Study Pilot","SP-CERN","Inclusion Criteria:\n\n* Male or female patients of all ages with a clinical and molecular diagnosis of hereditary spastic paraplegia type 4 (SPG4, SPAST) or hereditary spastic paraplegia type 5A (SPG5A, CYP7B1).\n\nExclusion Criteria:\n\n* Not having such a diagnosis and\u002For not being related to such individual.","ALL",{"count":19,"type":20},100,"ESTIMATED","2 Years","OBSERVATIONAL","The Spastic Paraplegia - Centers of Excellence Research Network (SP-CERN) is a collaborative research consortium dedicated to advancing the understanding, diagnosis, and treatment of hereditary spastic paraplegia (HSP) and primary lateral sclerosis (PLS). Aims of the consortium are to a) perform natural history studies of HSP subtypes, b) discover and validate biomarkers and clinician- and patient-reported outcome measures, c) uncover HSP's molecular pathophysiology and develop rational therapeutic targets, and d) perform sufficiently powered clinical trials. The current pilot study is aimed at enrolling 100 individuals with hereditary spastic paraplegia type 4 (SPG4) or hereditary spastic paraplegia type 5A (SPG5A).",[25,26,27,28,29,30,31,32,33],"Hereditary Spastic Paraplegia","Primary Lateral Sclerosis","SPG4","SPG5A","Spastic Paraplegia 4","Spastic Paraplegia 5A","Early Onset Hereditary Spastic Paraplegia","Neuromuscular Diseases","Spastic Paraplegia, Hereditary","RECRUITING","2026-03-16",{"date":37,"type":38},"2026-03-18","ACTUAL",{"date":40,"type":38},"2024-06-04",{"date":42,"type":20},"2027-06-04",{"name":44,"class":45},"Boston Children's Hospital","OTHER",11]